Smoking Cessation Pharmacotherapy Based on Genetically-Informed Biomarkers: What is the Evidence?

ABSTRACT:

Introduction

Pharmacogenomic studies have used genetic variants to identify smokers likely to respond to pharmacological treatments for smoking cessation.

Methods

We performed a systematic review and meta-analysis of primary and secondary analyses of trials of smoking cessation pharmacotherapies. Eligible were trials with data on a priori selected single nucleotide polymorphisms, replicated non-single nucleotide polymorphisms, and/or the nicotine metabolite ratio. We estimated the genotype × treatment interaction as the ratio of risk ratios (RRR) for treatment effects across genotype groups.

Results

We identified 18 trials (N = 9017 participants), including 40 active (bupropion, nicotine replacement therapy [NRT], varenicline, or combination therapies) versus placebo

SUBMITTER: Panagiotou OA 

PROVIDER: S-EPMC6698953 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature